Butamben

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Butamben
Accession Number
DB11148
Type
Small Molecule
Groups
Approved
Description

Butamben is a midly water-soluble local anesthetic that is thought to reversibly blocking nerve conduction. It is available in topical formulations in combination with other local anesthetics indicated for controlling pain or inducing anesthesia on mucous membranes for surgical or endoscopic procedures. The onset of drug action is intermediate compared to benzocaine or tetracaine.

Structure
Thumb
Synonyms
  • Butyl aminobenzoate
External IDs
NSC-128464
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cetacaine AnestheticButamben (.004 g/.2g) + Benzocaine (.028 g/.2g) + Tetracaine hydrochloride (.004 g/.2g)SolutionTopicalCetylite Industries, Inc.1960-01-01Not applicableUs
Cetacaine AnestheticButamben (.004 g/.2g) + Benzocaine (.028 g/.2g) + Tetracaine hydrochloride (.004 g/.2g)Aerosol, sprayTopicalCetylite Industries, Inc.1958-01-01Not applicableUs
Cetacaine LiquidButamben (2 %) + Benzocaine (14 %) + Tetracaine hydrochloride (2 %)LiquidTopicalCetylite Industries, Inc.1996-09-19Not applicableCanada
Cetacaine SprayButamben (2 %) + Benzocaine (14 %) + Tetracaine hydrochloride (2 %)AerosolTopicalCetylite Industries, Inc.1994-12-31Not applicableCanada
Cetacaine Topical AnestheticButamben (.004 g/.2g) + Benzocaine (.028 g/.2g) + Tetracaine hydrochloride (.004 g/.2g)GelTopicalCetylite Industries, Inc.1960-01-01Not applicableUs
Cetacaine Topical AnestheticButamben (.004 g/.2g) + Benzocaine (.028 g/.2g) + Tetracaine hydrochloride (.004 g/.2g)GelTopicalCetylite Industries, Inc.1960-01-01Not applicableUs
One Touch Advanced Topical Anesthetic Bubble GumButamben (4 mg/.2g) + Benzocaine (28 mg/.2g) + Tetracaine hydrochloride (4 mg/.2g)GelDental; TopicalHager Worldwide, Inc.2009-02-01Not applicableUs
One Touch Advanced Topical Anesthetic CherryButamben (4 mg/.2g) + Benzocaine (28 mg/.2g) + Tetracaine hydrochloride (4 mg/.2g)GelDental; TopicalHager Worldwide, Inc.2009-02-01Not applicableUs
One Touch Advanced Topical Anesthetic Gel Cool MintButamben (4 mg/.2g) + Benzocaine (28 mg/.2g) + Tetracaine hydrochloride (4 mg/.2g)GelDental; TopicalHager Worldwide, Inc.2009-02-01Not applicableUs
One Touch Advanced Topical Anesthetic Strawberry IceButamben (4 mg/.2g) + Benzocaine (28 mg/.2g) + Tetracaine hydrochloride (4 mg/.2g)GelDental; TopicalHager Worldwide, Inc.2009-02-01Not applicableUs
Categories
UNII
EFW857872Q
CAS number
94-25-7
Weight
Average: 193.246
Monoisotopic: 193.110278727
Chemical Formula
C11H15NO2
InChI Key
IUWVALYLNVXWKX-UHFFFAOYSA-N
InChI
InChI=1S/C11H15NO2/c1-2-3-8-14-11(13)9-4-6-10(12)7-5-9/h4-7H,2-3,8,12H2,1H3
IUPAC Name
butyl 4-aminobenzoate
SMILES
CCCCOC(=O)C1=CC=C(N)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Butamben.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Butamben.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Butamben.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Butamben.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Butamben.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Butamben is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Butamben is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Butamben.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Butamben is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Butamben.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Butamben is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butamben.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Butamben.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Butamben is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butamben.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Butamben is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Butamben.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butamben.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Butamben.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Butamben.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Butamben is combined with Azaperone.Investigational, Vet Approved
AzelastineButamben may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Butamben is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Butamben.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Butamben is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Butamben.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Butamben.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Butamben is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Butamben.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Butamben is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Butamben is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Butamben is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Butamben.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butamben.Approved, Investigational
BuprenorphineButamben may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Butamben.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butamben.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butamben is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butamben is combined with Butalbital.Approved, Illicit
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Butamben.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butamben.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Butamben.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butamben.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Butamben is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Butamben.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Butamben is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Butamben is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Butamben.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Butamben.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Butamben.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butamben.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Butamben is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butamben.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butamben.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Butamben is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butamben.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Butamben is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Butamben is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Butamben is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Butamben is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Butamben.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Butamben is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Butamben is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Butamben is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Butamben is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butamben.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Butamben is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Butamben.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Butamben.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Butamben.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Butamben is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butamben.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Butamben is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Butamben is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butamben.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Butamben is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Butamben.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Butamben.Approved
DesipramineThe risk or severity of adverse effects can be increased when Butamben is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Butamben is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Butamben is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Butamben is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Butamben is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butamben.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Butamben.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butamben.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Butamben.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Butamben.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Butamben is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Butamben is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butamben.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butamben.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butamben.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Butamben is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butamben.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butamben.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Butamben is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Butamben is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Butamben is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Butamben.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Butamben.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Butamben is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butamben.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Butamben.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Butamben is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Butamben is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Butamben is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Butamben.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Butamben is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Butamben is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Butamben.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butamben.Approved
EthanolButamben may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butamben.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Butamben is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Butamben is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Butamben.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Butamben is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Butamben.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butamben.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Butamben.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Butamben.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Butamben.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Butamben.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Butamben is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Butamben.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Butamben is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Butamben is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Butamben.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butamben.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Butamben is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Butamben is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Butamben is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Butamben.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Butamben is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Butamben.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Butamben is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butamben.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butamben.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butamben.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Butamben.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Butamben is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butamben.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Butamben is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Butamben.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butamben.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Butamben is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Butamben.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Butamben is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Butamben.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Butamben is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Butamben.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butamben.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Butamben.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Butamben.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Butamben.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Butamben.Approved, Investigational
HydrocodoneButamben may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butamben.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Butamben is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Butamben is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Butamben is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Butamben is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Butamben.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Butamben.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Butamben.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butamben.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Butamben is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Butamben is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Butamben.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Butamben is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Butamben is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Butamben is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butamben.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Butamben is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butamben.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Butamben.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Butamben.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Butamben.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Butamben is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Butamben is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butamben.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Butamben is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Butamben.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Butamben.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Butamben is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Butamben is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Butamben is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Butamben is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Butamben is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Butamben.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Butamben.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butamben.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butamben.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Butamben is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butamben.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Butamben is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Butamben.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Butamben.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Butamben.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Butamben.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Butamben is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butamben.Approved
MethotrimeprazineButamben may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butamben.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Butamben is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Butamben.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butamben.Approved
MetyrosineButamben may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Butamben.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Butamben is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved, Investigational
MirtazapineButamben may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Butamben.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Butamben.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butamben.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Butamben is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Butamben.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Butamben.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Butamben is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Butamben is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Butamben is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butamben.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Butamben is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butamben.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Butamben.Approved, Illicit
OrphenadrineButamben may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Butamben.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butamben.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Butamben is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Butamben.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Butamben.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butamben.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butamben.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butamben.Approved
ParaldehydeButamben may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Butamben is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Butamben is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butamben.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butamben.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
PerazineThe risk or severity of adverse effects can be increased when Butamben is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Butamben.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butamben.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Butamben.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Butamben is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Butamben is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butamben.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Butamben is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Butamben is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Butamben is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Butamben.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Butamben.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Butamben is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Butamben is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Butamben is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Butamben is combined with Pomalidomide.Approved
PramipexoleButamben may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Butamben.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Butamben.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butamben.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Butamben.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Butamben is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Butamben.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butamben.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Butamben.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Butamben is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Butamben is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butamben.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Butamben.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Butamben.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Butamben is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Butamben is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Butamben.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Butamben.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butamben.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Butamben is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Butamben is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Butamben is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butamben.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butamben.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butamben.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Butamben.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Butamben is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Butamben is combined with Romifidine.Vet Approved
RopiniroleButamben may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butamben.Approved
RotigotineButamben may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Butamben.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Butamben is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butamben.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Butamben is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Butamben.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Butamben is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butamben.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
StiripentolThe risk or severity of adverse effects can be increased when Butamben is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butamben.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butamben.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Butamben is combined with Sultopride.Experimental
SuvorexantButamben may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Butamben is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Butamben is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptButamben may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Butamben.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Butamben is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Butamben.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Butamben is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Butamben.Investigational
ThalidomideButamben may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butamben.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Butamben.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butamben.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Butamben.Approved
TiagabineThe risk or severity of adverse effects can be increased when Butamben is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Butamben is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Butamben is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Butamben is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Butamben is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Butamben is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Butamben is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Butamben.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Butamben.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butamben.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Butamben.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Butamben.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Butamben is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Butamben is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butamben.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Butamben is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butamben.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Butamben is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Butamben is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Butamben.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Butamben is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Butamben is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Butamben is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Butamben is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butamben.Approved
XenonThe risk or severity of adverse effects can be increased when Butamben is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Butamben is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butamben.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Butamben is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Butamben is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butamben.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Butamben is combined with Zolazepam.Vet Approved
ZolpidemButamben may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Butamben is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Butamben.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Butamben.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Butamben.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Beekwilder JP, van Kempen GT, van den Berg RJ, Ypey DL: The local anesthetic butamben inhibits and accelerates low-voltage activated T-type currents in small sensory neurons. Anesth Analg. 2006 Jan;102(1):141-5. [PubMed:16368819]
External Links
KEGG Compound
C07875
PubChem Compound
2482
PubChem Substance
347827919
ChemSpider
2388
ChEBI
3231
ChEMBL
CHEMBL127516

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Aerosol, sprayTopical
SolutionTopical
LiquidTopical
AerosolTopical
GelTopical
GelDental; Topical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.336 mg/mLALOGPS
logP2.88ALOGPS
logP2.47ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)2.76ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.32 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity56.66 m3·mol-1ChemAxon
Polarizability21.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-00dr-2900000000-906b8d78dc5d3ad39b7d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Aminobenzoic acids and derivatives / Benzoyl derivatives / Aniline and substituted anilines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Primary amines / Organopnictogen compounds / Organooxygen compounds / Organic oxides
show 1 more
Substituents
Aminobenzoic acid or derivatives / Benzoate ester / Benzoyl / Aniline or substituted anilines / Amino acid or derivatives / Carboxylic acid ester / Carboxylic acid derivative / Monocarboxylic acid or derivatives / Amine / Organonitrogen compound
show 8 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
substituted aniline, primary amino compound, benzoate ester, amino acid ester (CHEBI:3231)

Drug created on December 03, 2015 09:51 / Updated on December 01, 2017 16:17